CLINICAL GUIDELINES FOR FAMILIAL HYPERCHOLESTEROLEMIA

These guidelines represent all current aspects of etiology, diagnosis, and treatment of the clinical and statistical group of familial hypercholesterolemia in both adults and children in accordance with the requirements of the Ministry of Health of Russia.

familial hypercholesterolemia, atherosclerosis, coronary heart disease, low density lipoprotein cholesterol, xanthomas

1. Ezhov M.V., Sergienko I.V., Rozhkova T.A., Kukharchuk V.V., Konovalov G.A., Meshkov A.N., Ershov A.I., Gurevich V.S., Konstantinov V.O., Sokolov A.A., Shcherbakova M.Yu., Leontyeva I.V., Bazhan S.S., Voevoda M.I., Shaposhnik I.I. Russian recommendations on the diagnosis and treatment of familial hypercholesterolemia. Atherosclerosis and dyslipidemia. 2016. Vol. 4 P. 21 – 29. Russian

2. Yuan G., Wang J., Hegele R.A. Heterozygous familial hypercholesterolemia: an underrecognized cause of early cardiovascular disease// CMAJ. 2006. 174 (8). 1124–1129.

3. Goldberg A.C., Hopkins P.N., Toth P.P., Ballantyne C.M., Rader D.J., Robinson J.G., Daniels S.R., Gidding S.S., de Ferranti S.D., Ito M.K., McGowan M.P., Moriarty P.M., Cromwell W.C., Ross J.L., Ziajka P.E.; National Lipid Association Expert Panel on Familial Hypercholesterolemia. Familial hypercholesterolemia: screening, diagnosis and management of pediatric and adultpatients: clinical guidance from the National Lipid Association Expert Panel on Familial Hypercholesterolemia // J. Clin. Lipidol. 2011. 5 (3 Suppl): S1–8. doi: 10.1016/j.jacl.2011.04.003.

4. Civeira F. Guidelines for the diagnosis and management of heterozygous familial hypercholesterolemia // Atherosclerosis. 2004. 173. 1. 55–68.

5. Kukharchuk V.V., Malyshev P.P., Meshkov A.N. Familial hypercholesterolemia: current aspects of diagnosis, prophylaxis and therapy // Cardiology. 2009. 49, 1. 76–83. Russian.

6. Yuan G., Wang J., Hegele R.A. Heterozygous familial hypercholesterolemia: an underrecognized cause of early cardiovascular disease // CMAJ. 2006. 174, 8. 1124–1129.

7. Hopkins P.N., Toth P.P., Ballantyne C.M., Rader D.J. Familial hypercholesterolemias: prevalence, genetics, diagnosis and screening recommendations from the National Lipid Association Expert Panel on FamilialHypercholesterolemia // J. Clin. Lipidol. 2011. 5, 3 Suppl. S9–17.

8. Myant N.B. Familial defective apolipoprotein B-100: a review, including some comparisons with familial hypercholesterolaemia // Atherosclerosis. 1993. 104, 1-2. 1–18.

9. Merino-Ibarra E., Castillo S., Mozas P., Cenarro A., Martorell E., Díaz J.L., Suárez-Tembra M., Alonso R., Civeira F., Mata P., Pocoví M. Screening of APOB gene mutations in subjects with clinical diagnosis of familialhypercholesterolemia // Hum. Biol. 2005. 77, 5. 663–73.

10. Soufi M., Sattler A.M., Maerz W., Starke A., Herzum M., Maisch B., Schaefer J.R. A new but frequent mutation of apoB-100-apoB His3543Tyr. // Atherosclerosis. 2004. 74, 1. 11.

11. Burnett J.R., Hooper A.J. Common and rare gene variants affecting plasma LDL cholesterol // Clin. Biochem. Rev. 2008. 29, 1. 11–12.

12. Mandelstam, M.Yu., Vasiliev V.B. Monogenic hypercholesterolemia: new genes, new targets for treatment // Genetics. 2008. 44, 10. 1309–1316. Russian

13. Maxwell K.N., Fisher E.A., Breslow J.L. Overexpression of PCSK9 accelerates the degradation of the LDLR in a post-endoplasmic reticulum compartment // Proc. Natl. Acad. Sci. U.S.A. 2005;102(6):2069-74.

14. Ouguerram K., Chetiveaux M., Zair Y., Costet P., Abifadel M., Varret M., Boileau C., Magot T., Krempf M. Apolipoprotein B100 metabolism in autosomal-dominant hypercholesterolemia related to mutations in PCSK9 // Arterioscler. Thromb. Vasc. Biol. 2004;24(8):1448-53.

15. Goldstein J.L., Hobbs H.H., Brown M.S. Familial hypercholesterolemia. In Scriver CR, Beaudet AL, Sly WS, Valle D. eds, The Metabolic and Molecular Bases of Inherited Disease, 8th ed. New York: McGraw-Hill Information Services Company, 2001, p. 2863 –2913.

16. Abifadel M., Rabиs J.P., Devillers M., Munnich A., Erlich D., Junien C., Varret M., Boileau C. Mutations and polymorphisms in the proprotein convertase subtilisin kexin 9 (PCSK9) gene in cholesterol metabolism and disease // Hum. Mutat. 2009;30(4):520-9.

17. Sharifi M., Futema M., Nair D., Humphries S.E. Genetic Architecture of Familial Hypercholesterolaemia // Curr. Cardiol. Rep. 2017;19(5):44.

18. Meshkov A.I., Ershov A.I., Shcherbakova N.V., Rozhkova T.A., Kalinina M.V., Malyshev P.P., Kukharchuk V.V., Boytsov S.A. Phenotypic features of the course of heterozygous forms of familial hypercholesterolemia in carriers of mutations of the LDLR and APOB genes // Cardiovasc. Therapy and Prevention. 2011; 10 (8): 63–65. Russian

19. Kukharchuk V.V. Etiology and pathogenesis of atherosclerosis. Guide to atherosclerosis and coronary heart disease. Eds. E.I. Chazov, V.V. Kukharchuk, S.A. Boytsov. M .: Media Medica, 2007. 736 p. Russian

20. Nordestgaard B.G., Chapman M.J., Humphries S.E., Ginsberg H.N., Masana L., Descamps O.S., Wiklund O., Hegele R.A., Raal F.J., Defesche J.C., Wiegman A., Santos R.D., Watts G.F., Parhofer K.G., Hovingh G.K., Kovanen P.T., Boileau C., Averna M., Borén J., Bruckert E., Catapano A.L., Kuivenhoven J.A., Pajukanta P., Ray K., Stalenhoef A.F., Stroes E., Taskinen M.R., Tybjærg-Hansen A.; European Atherosclerosis Society Consensus Panel. Familial hypercholesterolaemia is underdiagnosed and undertreated in the general population: guidance for clinicians to prevent coronary heart disease: consensus statement of the European Atherosclerosis Society // Eur. Heart J. 2013;34(45):3478-90a.

21. Sijbrands E.J., Westendorp R.G., Paola Lombardi M., Havekes L.M., Frants R.R., Kastelein J.J., Smelt A.H. Additional risk factors influence excess mortality in heterozygous familial hypercholesterolaemia // Atherosclerosis. 2000;149(2):421-5.

22. Humphries S.E., Cranston T., Allen M., MiddletonPrice H., Fernandez M.C., Senior V., Hawe E., Iversen A., Wray R., Crook M.A., Wierzbicki A.S. Mutational analysis in UK patients with a clinical diagnosis of familialhypercholesterolaemia: relationship with plasma lipid traits, heart disease risk and utility in relative tracing // J. Mol. Med. (Berl). 2006;84(3):203–14.

23. Ershova A.I., Meshkov A.N., Bazhan S.S., Storozhok M.A., Efanov A.Y., Medvedeva I.V., Indukaeva E.V., Danilchenko Y.V., Kuzmina O.K., Barbarash O.L., Deev A.D., Shalnova S.A., Boytsov S.A. The prevalence of familial hypercholesterolemia in the West Siberian region of the Russian Federation: A substudy of the ESSE-RF // PLoS One. 2017;12(7):e0181148.

24. Slack J. Risks of ischaemic heart-disease in familial hyperlipoproteinaemic states // Lancet. 1969;2(7635):1380-2.

25. Widhalm K., Dirisamer A., Lindemayr A., Kostner G. Diagnosis of families with familial hypercholesterolaemia and/or Apo B-100 defect by means of DNA analysis of LDL-receptor gene mutations // J. Inherit. Metab. Dis. 2007;30(2):239-47.

26. Мешков А.Н., Малышев П.П., Кухарчук В.В. Семейная гиперхолестеринемия в России: генетическая и фенотипическая характеристика // Терапевт. арх. 2009;81(9):23-8.

27. Ezhov M.V., Sergienko, I.V., Aronov, D.M., Arabidze G.G., Akhmedzhanov, N.M., Bazhan S.S., Balakhonova T.V., Barbarash O.L., Boytsov S.A., Bubnova M.G., Voevoda M.I., Galyavich A.S., Gornyakova N.B., Gurevich V.S., Drapkina O.M., Duplyakov D.V., Eregin S.Ya., Zubareva M.Yu., Karpov R.S, Karpov Yu.A., Koziolova N.A., Konovalov G.A., Konstantinov V.O., Kosmacheva E.D., Martynov A.I., Nebieridze D.V., Pokrovsky S.N., Ragino Yu.I., Skibitsky V.V., Smolenskaya O.G., Chazova I.E., Shalnova S.A., Shaposhnik I.I., Kukharchuk V.V. Diagnosis and correction of lipid metabolism disorders for the prevention and treatment of atherosclerosis. Russian recommendations VI revision // Atherosclerosis and Dyslipidemia. 2017; 3: 5–22. Russian

28. Catapano A.L., Graham I., de Backer G., Wiklund O., Chapman M.J., Drexel H., Hoes A.W., Jennings C.S., Landmesser U., Pedersen T.R., Reiner Ž., Riccardi G., Taskinen M.R., Tokgozoglu L., Verschuren W.M., Vlachopoulos C., Wood D.A., Zamorano J.L.; Authors/Task Force Members; Additional Contributor. 2016 ESC/EAS Guidelines for the Management of Dyslipidaemias // Eur. Heart. J. 2016;37(39):2999– 3058.

29. Watts G.F., Gidding S., Wierzbicki A.S., Toth P.P., Alonso R., Brown W.V., Bruckert E., Defesche J., Lin K.K., Livingston M., Mata P., Parhofer K.G., Raal F.J., Santos R.D., Sijbrands E.J., Simpson W.G., Sullivan D.R., Susekov A.V., Tomlinson B., Wiegman A., Yamashita S., Kastelein J.J.; International FH Foundation. Integrated guidance on the care of familial hypercholesterolaemia from the International FH Foundation: executive summary // J. Atheroscler. Thromb. 2014;21(4):368–74.

30. Familial hypercholesterolaemia: identification and management. NICE guideline, 2008 https://www. nice.org.uk/guidance/cg71/resources/familial-hypercholesterolaemia-identification-and-managementpdf-975623384005

31. Cuchel M., Bruckert E., Ginsberg H.N., Raal F.J., Santos R.D., Hegele R.A., Kuivenhoven J.A., Nordestgaard B.G., Descamps O.S., Steinhagen-Thiessen E., Tybjærg-Hansen A., Watts G.F., Averna M., Boileau C., Borén J., Catapano A.L., Defesche J.C., Hovingh G.K., Humphries S.E., Kovanen P.T., Masana L., Pajukanta P., Parhofer K.G., Ray K.K., Stalenhoef A.F., Stroes E., Taskinen M.R., Wiegman A., Wiklund O., Chapman M.J.; European Atherosclerosis Society Consensus Panel on Familial Hypercholesterolaemia. Homozygous familial hypercholesterolaemia: new insights and guidance for clinicians to improve detection and clinical management. A position paper from the Consensus Panel on Familial Hypercholesterolaemia of the European Atherosclerosis Society // Eur. Heart. J. 2014;35(32):2146-57.

32. Karpov Yu.A., Kukharchuk V.V., Boytsov S.A., Voevoda M.I., Gafarov V.V., Gurevich V.S., Ezhov M.V., Kashtalap V.V., Kozlov A.A., Konovalov G.A., Konstantinov V.O., Korneva V.A., Leontyeva I.V., Likhomanov K.S., Malyshev P.P., Meshkov A.N., Pokrovsky S.N., Safarova M.S., Sergienko I.V., Sokolov A.A., Susekov A.V., Shcherbakova M.Yu. The conclusion of the council of experts of the national society for the study of atherosclerosis (PLA). Familial hypercholesterolemia in the Russian Federation: unsolved problems of diagnosis and treatment // Atherosclerosis and Dyslipidemia. 2015; 2 (19): 5–16. Russian

33. Montalescot G., Sechtem U., Achenbach S., Andreotti F., Arden C., Budaj A., Bugiardini R., Crea F., Cuisset T., di Mario C., Ferreira J.R., Gersh B.J., Gitt A.K., Hulot J.S., Marx N., Opie L.H., Pfisterer M., Prescott E., Ruschitzka F., Sabaté M., Senior R., Taggart D.P., van der Wall E.E., Vrints C.J.; ESC Committee for Practice Guidelines, Zamorano J.L., Achenbach S., Baumgartner H., Bax J.J., Bueno H., Dean V., Deaton C., Erol C., Fagard R., Ferrari R., Hasdai D., Hoes A.W., Kirchhof P., Knuuti J., Kolh P., Lancellotti P., Linhart A., Nihoyannopoulos P., Piepoli M.F., Ponikowski P., Sirnes P.A., Tamargo J.L., Tendera M., Torbicki A., Wijns W., Windecker S.; Document Reviewers, Knuuti J., Valgimigli M., Bueno H., Claeys M.J., Donner-Banzhoff N., Erol C., Frank H., Funck-Brentano C., Gaemperli O., Gonzalez-Juanatey J.R., Hamilos M., Hasdai D., Husted S., James S.K., Kervinen K., Kolh P., Kristensen S.D., Lancellotti P., Maggioni A.P., Piepoli M.F., Pries A.R., Romeo F., Rydén L., Simoons M.L., Sirnes P.A., Steg P.G., Timmis A., Wijns W., Windecker S., Yildirir A., Zamorano J.L. 2013 ESC guidelines on the management of stable coronary artery disease: the Task Force on the management of stable Coronary artery disease of European Society of Cardiology // Eur. Heart. J. 2013; 34: 2949–3003.

34. Landmesser U., Chapman M.J., Farnier M., Gencer B., Gielen S., Hovingh G.K., Lüscher T.F., Sinning D., Tokgözoglu L., Wiklund O., Zamorano J.L., Pinto F.J., Catapano A.L.; European Society of Cardiology (ESC); European Atherosclerosis Society (EAS). European Society of Cardiology/European Atherosclerosis Society Task Force consensus statement on proprotein convertase subtilisin/kexin type 9 inhibitors: practical guidance for use in patients at very high cardiovascular risk // Eur. Heart. J. 2017;38(29):2245– 2255.

35. Aronov D.M., Bubnova M.G., Krasnitsky V.B. New approaches to rehabilitation and secondary prophylaxis in patients after acute myocardial infarction with elevation of the ST segment of the electrocardiogram // Cardiology. 2015; 55 (12): 125-132. Russian.

36. Leon A.S., Franklin B.A., Costa F., Balady G.J., Berra K.A., Stewart K.J., Thompson P.D., Williams M.A., Lauer M.S. Cardiac rehabilitation and secondary prevention of coronary heart disease: an American Heart Association scientific statement from the Council on Clinical Cardiology (Subcommittee on Exercise, Cardiac Rehabilitation, and Prevention) and the Council on Nutrition, Physical Activity, and Metabolism (Subcommittee on Physical Activity), in collaboration with the American association of Cardiovascular and Pulmonary Rehabilitation // Circulation. 2005;111:369—376.

37. Anderson L., Oldridge N., Thompson D.R., Zwisler A.D., Rees K., Martin N., Taylor R.S. Exercise-Based Cardiac Rehabilitation for Coronary Heart Disease: Cochrane Systematic Review and Meta-Analysis // J. Am. Coll. Cardiol. 2016;67(1):1-12.

38. Bruckert E., Saheb S., Bontè J.R., Coudray-Omnès C. Daily life, experience and needs of persons suffering from homozygous familial hypercholesterolaemia: insights from a patient survey // Atheroscler. Suppl. 2014;15(2):46-51.

39. Agård A, Bolmsjö I.A., Hermerén G., Wahlstöm J. Familial hypercholesterolemia: ethical, practical and psychological problems from the perspective of patients // Patient. Educ. Couns. 2005;57(2):162-7.

40. Andersen L.K., Jensen H.K., Juul S., Faergeman O. Patients’ attitudes toward detection of heterozygous familial hypercholesterolemia // Arch. Intern. Med. 1997;157(5):553-60.

41. Frich J.C., Malterud K., Fugelli P. Experiences of guilt and shame in patients with familial hypercholesterolemia: a qualitative interview study // Patient. Educ. Couns. 2007;69(1-3):108-13.

42. Hagger M.S., Hardcastle S.J., Hingley C., Strickland E., Pang J., Watts G.F. Predicting Self-Management Behaviors in Familial Hypercholesterolemia Using an Integrated Theoretical Model: the Impact of Beliefs About Illnesses and Beliefs About Behaviors // Int. J. Behav. Med. 2016;23(3):282-294.

43. Boytsov S.A., Martsevich S.Yu., Kutishenko N.P., Drozdova L.Yu., Lukyanov M.M., Zagrebelny A.V., Ginzburg M.L. Registers in cardiology. Basic rules of conduct and real opportunities // Cardiovascular. Therapy and Prevention, 2013;12(1):4-9. Russian

44. EAS Familial Hypercholesterolaemia Studies Collaboration. Pooling and expanding registries of familial hypercholesterolaemia to assess gaps in care and improve disease management and outcomes: Rationale and design of the global EAS Familial Hypercholesterolaemia Studies Collaboration // Atheroscler. Suppl. 2016;22:1-32.

45. Marteau T., Senior V., Humphries S.E., Bobrow M., Cranston T., Crook M.A., Day L., Fernandez M., Horne R., Iversen A., Jackson Z., Lynas J., Middleton-Price H., Savine R., Sikorski J., Watson M., Weinman J., Wierzbicki A.S., Wray R. Psychological impact of genetic testing for familial hypercholesterolemia within a previously aware population: a randomized controlled trial // Am. J. Med. Genet. A. 2004;128A(3):285-93.

46. Suárez Bagnasco M. Psychological issues and cognitive impairment in adults with familial hypercholesterolemia // Fam. Pract. 2017;34(5):520-524.

47. Piepoli M.F., Hoes A.W., Agewall S., Albus C., Brotons C., Catapano A.L., Cooney M.T., Corrа U., Cosyns B., Deaton C., Graham I., Hall M.S., Hobbs F.D., Løchen M.L., Löllgen H., Marques-Vidal P., Perk J., Prescott E., Redon J., Richter D.J., Sattar N., Smulders Y., Tiberi M., van der Worp H.B., van Dis I., Verschuren W.M. 2016 European Guidelines on cardiovascular disease prevention in clinical practice: The Sixth Joint Task Force of the European Society of Cardiology and Other Societies on Cardiovascular Disease Prevention in Clinical Practice (constituted by representatives of 10 societies and by invited experts)Developed with the special contribution of the European Association for Cardiovascular Prevention & Rehabilitation (EACPR) // Eur. Heart. J. 2016;37(29):2315-81.

48. Antithrombotic Trialists’ Collaboration, Baigent C., Blackwell L., Collins R., Emberson J., Godwin J., Peto R., Buring J., Hennekens C., Kearney P., Meade T., Patrono C., Roncaglioni M.C., Zanchetti A. Aspirin in the primary and secondary prevention of vascular disease: collaborative meta-analysis of individual participant data from randomised trials // Lancet 2009;373:1849 –1860.

49. Nishimura R.A., Otto C.M., Bonow R.O., Carabello B.A., Erwin J.P. 3rd, Guyton R.A., O’Gara P.T., Ruiz C.E., Skubas N.J., Sorajja P., Sundt T.M. 3rd, Thomas J.D.; ACC/AHA Task Force Members. 2014 AHA/ACC Guideline for the Management of Patients With Valvular Heart Disease: executive summary: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines. Circulation // 2014;129(23):2440-92.

50. Clinical supervision of patients with chronic noncommunicable diseases and patients at high risk of their development. Guidelines / ed. S.A. Boytsova and A.G. Chuchalina. 112 s. Internet resource: http://www.gnicpm.ru, http://www.ropniz.ru/ Russian

51. Wiegman A., Gidding S.S., Watts G.F., Chapman M.J., Ginsberg H.N., Cuchel M., Ose L., Averna M., Boileau C., Borén J., Bruckert E., Catapano A.L., Defesche J.C., Descamps O.S., Hegele R.A., Hovingh G.K., Humphries S.E., Kovanen P.T., Kuivenhoven J.A., Masana L., Nordestgaard B.G., Pajukanta P., Parhofer K.G., Raal F.J., Ray K.K., Santos R.D., Stalenhoef A.F., Steinhagen-Thiessen E., Stroes E.S., Taskinen M.R., Tybjærg-Hansen A., Wiklund O.; European Atherosclerosis Society Consensus Panel. Familial hypercholesterolaemia in children and adolescents: gaining decades of life by optimizing detection and treatment / Eur. Heart J. 2015;36(36):2425-37.

52. Meshkov A.N., Ershova A.I., Deev A.D., Metelskaya V.A., Zhernakova Yu.V., Rotar O.P., Shalnova S.A., Boytsov S.A. Distribution of lipid spectrum of men and women of working age in the Russian Federation: results of the ESSE-RF study for 2012-2014 // Cardiovascular Therapy and Prevention. 2017; 16 (4): 62–67).

53. Meshkov V.N., Ershov A.I., Shcherbakova N.V., Rozhkova T.A., Kalinina M.V., Kukharchuk V.V., Boytsov S.A. Phenotypic features of the course of heterozygous forms of familial hypercholesterolemia in carriers of the mutation of the LDLR and APOB genes // Cardiovascular Therapy and Prevention 2011; 10 (8): 63–65. Russian

54. Schwartz J., Padmanabhan A., Balogun R.A., Connelly-Smith L., Delaney M., Dunbar N.M., Witt V., Wu Y., Shaz B.H. Guidelines on the Use of Therapeutic Apheresis in Clinical Practice-Evidence-Based Approach from the Writing Committee of the American Society for Apheresis: The Seventh Special Issue // J. Clin. Apher. 2016;31(3):149–162.

55. Shakhtshneider E.V., Makarenkova K.V., Astrakova K.S., Ivanoshuk D.Ye., Orlov P.S., Ragino Y.I., Voevoda M.I. Target sequencing of the PCSK9 gene in patients with familial hypercholesterolemia in Russia // Cardiology. 2017; 57 (6): 46-51. Russian.

56. Shakhtshneider E.V., Ivanoshuk D.E., Makarenkova K.V., Orlov P.S., Timoschenko O.V., Bazhan S.S., Nikitin Yu.P., Voevoda M.I. Cascade genetic screening in the diagnosis of heterozygous forms of familial hypercholesterolemia: a clinical case // Rus. J. Cardiol. 2017; 146 (6): 178–179. Russian.

57. Aboyans V., Ricco J.B., Bartelink M.E.L., Björck M., Brodmann M., Cohnert T., Collet J.P., Czerny M., de Carlo M., Debus S., Espinola-Klein C., Kahan T., Kownator S., Mazzolai L., Naylor A.R., Roffi M., Röther J., Sprynger M., Tendera M., Tepe G., Venermo M., Vlachopoulos C., Desormais I., Document Reviewers, Widimsky P., Kolh P., Agewall S., Bueno H., Coca A., de Borst G.J., Delgado V., Dick F., Erol C., Ferrini M., Kakkos S., Katus H.A., Knuuti J., Lindholt J., Mattle H., Pieniazek P., Piepoli M.F., Scheinert D., Sievert H., Simpson I., Sulzenko J., Tamargo J., Tokgozoglu L., Torbicki A., Tsakountakis N., Tuсуn J., de Ceniga M.V., Windecker S., Zamorano J.L. 2017 ESC Guidelines on the Diagnosis and Treatment of Peripheral Arterial Diseases, in collaboration with the European Society for Vascular Surgery (ESVS) // Eur. J. Vasc. Endovasc. Surg. 2018;55(3):305-368. doi: 10.1016/j.ejvs.2017.07.018.

58. De Ferranti S.D., Rodday A.M., Mendelson M.M., Wong J.B., Leslie L.K., Sheldrick R.C. Prevalence of familial hypercholesterolemia in the 1999 to 2012 United States National Health and Nutrition Examination Surveys (NHANES) // Circulation. 2016;133:1067–1072.

59. Sjouke B., Kusters D.M., Kindt I., Besseling J., Defesche J.C., Sijbrands E.J., Roeters van Lennep J.E., Stalenhoef A.F., Wiegman A., de Graaf J., Fouchier S.W., Kastelein J.J., Hovingh G.K. Homozygous autosomal dominant hypercholesterolaemia in the Netherlands: prevalence, genotype-phenotype relationship, and clinical outcome // Eur. Heart J. 2015; 36(9):560–5.

60. Benn M., Watts G.F., Tybjaerg-Hansen A., Nordestgaard B.G. Familial hypercholesterolemia in the Danish general population: prevalence, coronary artery disease, and cholesterol-lowering medication. // J. Clin. Endocrinol. Metab. 2012; 97(11):3956–64.

61. Corrigendum // J. Clin. Endocrinol. Metab. 2014;99(12):4758–4759.

62. Akioyamen L.E., Genest J., Shan S.D., Reel R.L., Albaum J.M., Chu A., Tu J.V. Estimating the prevalence of heterozygous familial hypercholesterolaemia: a systematic review and meta-analysis // BMJ Open. 2017;7(9):e016461.

63. Mozaffarian D., Micha R., Wallace S. Effects on coronary heart disease of increasing polyunsaturated fat in place of saturated fat: a systematic review and meta-analysis of randomized controlled trials // PLoS Med. 2010;7:e1000252.

64. Estruch R., Ros E., Salas-Salvado J., Covas M.I., Corella D., Aros F., Gomez-Gracia E., Ruiz-Gutierrez V., Fiol M., Lapetra J., Lamuela-Raventos R.M., Serra-Majem L., Pinto X., Basora J., Munoz M.A., Sorlı J.V., Martınez J.A., MartınezGonzalez M.A. Primary prevention of cardiovascular disease with a Mediterranean diet // N. Engl. J. Med. 2013;368:1279–1290.

65. Mozaffarian D., Aro A., Willett W.C. Health effects of trans-fatty acids: experimental and observational evidence // Eur. J. Clin. Nutr. 2009;63(Suppl 2):S5– S21.

66. Keys A. Serum cholesterol response to dietary cholesterol // Am. J. Clin. Nutr. 1984;40:351–359.

67. Hollaender P.L., Ross A.B., Kristensen M. Wholegrain and blood lipid changes in apparently healthy adults: a systematic review and meta-analysis of randomized controlled studies // Am. J. Clin. Nutr. 2015;102:556–572.

68. Brown L., Rosner B., Willett W.W., Sacks F.M. Cholesterol-lowering effects of dietary fiber: a metaanalysis // Am. J. Clin. Nutr. 1999;69:30–42.

69. Gylling H., Plat J., Turley S., Ginsberg H.N., Ellegard L., Jessup W., Jones P.J., Lutjohann D., Maerz W., Masana L., Silbernagel G., Staels B., Boren J., Catapano A.L., De Backer G., Deanfield J., Descamps O.S., Kovanen P.T., Riccardi G., Tokgozoglu L., Chapman M.J. Plant sterols and plant stanols in the management of dyslipidaemia and prevention of cardiovascular disease // Atherosclerosis. 2014;232:346–360.

70. Musa-Veloso K., Poon T.H., Elliot J.A., Chung C. A comparison of the LDL-cholesterol lowering efficacy of plant stanols and plant sterols over a continuous dose range: results of a meta-analysis of randomized, placebo-controlled trials // Prostaglandins Leukot Essent Fatty Acids. 2011;85:9–28

71. Shaw K., Gennat H., O’Rourke P., Del Mar C. Exercise for overweight or obesity // Cochrane Database Syst. Rev. 2006;4:CD003817.

72. Yu-Poth S., Zhao G., Etherton T., Naglak M., Jonnalagadda S., Kris-Etherton P.M. Effects of the National Cholesterol Education Program’s Step I and Step II dietary intervention programs on cardiovascular disease risk factors: a meta-analysis // Am. J. Clin. Nutr. 1999;69: 632–646.

73. Kelley G.A., Kelley K.S. Impact of progressive resistance training on lipids and lipoproteins in adults: another look at a meta-analysis using prediction intervals // Prev. Med. 2009;49:473–475.

74. Maeda K., Noguchi Y., Fukui T. The effects of cessation from cigarette smoking on the lipid and lipoprotein profiles: a meta-analysis // Prev. Med. 2003;37:283–290.

75. Prescott E., Hippe M., Schnohr P., Hein H.O., Vestbo J. Smoking and risk of myocardial infarction in women and men: longitudinal population study // BMJ. 1998;316: 1043–1047.

76. Doll R., Peto R., Boreham J., Sutherland I. Mortality in relation to smoking: 50 years observations on male British doctors // BMJ. 2004;328:1519.

77. He J., Vupputuri S., Allen K., Prerost M.R., Hughes J., Whelton P.K. Passive smoking and the risk of coronary heart disease—a meta-analysis of epidemiologic studies // N. Engl. J. Med. 1999;340:920–926.

78. Law M.R., Morris J.K., Wald N.J. Environmental tobacco smoke exposure and ischaemic heart disease: an evaluation of the evidence // BMJ. 1997;315:973–980.

79. Cahill K., Stevens S., Perera R., Lancaster T. Pharmacological interventions for smoking cessation: an overview and network meta-analysis // Cochrane Database Syst. Rev. 2013;5:CD009329.

80. Mills E.J., Rachlis B., Wu P., Devereaux P.J., Arora P., Perri D. Primary prevention of cardiovascular mortality and events with statin treatments: a network meta-analysis involving more than 65,000 patients // J. Am. Coll. Cardiol. 2008;52: 1769–1781.

81. Versmissen J., Oosterveer D.M., Yazdanpanah M., Defesche J.C., Basart D.C., Liem A.H., Heeringa J., Witteman J.C., Lansberg P.J., Kastelein J.J., Sijbrands E.J. Efficacy of statins in familial hypercholesterolaemia: a long term cohort study // BMJ. 2008;337:a2423.

82. Boekholdt S.M., Hovingh G.K., Mora S., Arsenault B.J., Amarenco P., Pedersen T.R., LaRosa J.C., Waters D.D., DeMicco D.A., Simes R.J., Keech A.C., Colquhoun D., Hitman G.A., Betteridge D.J., Clearfield M.B., Downs J.R., Colhoun H.M., Gotto A.M. Jr, Ridker P.M., Grundy S.M., Kastelein J.J. Very low levels of atherogenic lipoproteins and the risk for cardiovascular events: a meta-analysis of statin trials // J. Am. Coll. Cardiol. 2014;64:485–494.

83. Cholesterol Treatment Trialists’ (CTT) Collaboration, Baigent C., Blackwell L., Emberson J., Holland L.E., Reith C., Bhala N., Peto R., Barnes E.H., Keech A., Simes J., Collins R. Efficacy and safety of more intensive lowering of LDL cholesterol: a meta-analysis of data from 170,000 participants in 26 randomised trials // Lancet. 2010;376:1670–1681.

84. Cholesterol Treatment Trialists’ (CTT) Collaboration, Fulcher J., O’Connell R., Voysey M., Emberson J., Blackwell L., Mihaylova B., Simes J., Collins R., Kirby A., Colhoun H., Braunwald E., La Rosa J., Pedersen T.R., Tonkin A., Davis B., Sleight P., Franzosi M.G., Baigent C., Keech A. Efficacy and safety of LDL-lowering therapy among men and women: metaanalysis of individual data from 174,000 participants in 27 randomised trials // Lancet. 2015;385:1397–1405

85. Smilde T.J., van Wissen S., Wollersheim H., Trip M.D., Kastelein J.J., Stalenhoef A.F. Effect of aggressive versus conventional lipid lowering on atherosclerosis progression in familial hypercholesterolaemia (ASAP): a prospective, randomised, double-blind trial // Lancet. 2001;357: 577–81.

86. LaRosa J.C., He J., Vupputuri S. Effect of statins on risk of coronary disease: a meta-analysis of randomized controlled trials // JAMA. 1999;282:2340– 2346.

87. Giugliano R.P., Pedersen T.R., Park J.G., de Ferrari G.M., Gaciong Z.A., Ceska R., Toth K., GouniBerthold I., Lopez-Miranda J., Schiele F., Mach F., Ott B.R., Kanevsky E., Pineda A.L., Somaratne R., Wasserman S.M., Keech A.C., Sever P.S., Sabatine M.S.; FOURIER Investigators. Clinical efficacy and safety of achieving very low LDL-cholesterol concentrations with the PCSK9 inhibitor evolocumab: a prespecified secondary analysis of the FOURIER trial // Lancet. 2017;390(10106):1962–1971.

88. Giugliano R.P., Keech A., Murphy S.A., Huber K., Tokgozoglu S.L., Lewis B.S., Ferreira J., Pineda A.L., Somaratne R., Sever P.S., Pedersen T.R., Sabatine M.S. Clinical Efficacy and Safety of Evolocumab in High-Risk Patients Receiving a Statin: Secondary Analysis of Patients With Low LDL Cholesterol Levels and in Those Already Receiving a Maximal-Potency Statin in a Randomized Clinical Trial // JAMA Cardiol. 2017;2(12):1385–1391.

89. The Lipid Research Clinics Coronary Primary Prevention Trial results. I. Reduction in incidence of coronary heart disease // JAMA 1984;251: 351–364.

90. Tyroler H.A. Cholesterol and cardiovascular disease. An overview of Lipid Research Clinics (LRC) epidemiologic studies as background for the LRC Coronary Primary Prevention Trial // Am. J. Cardiol. 1984;54:14C–19C.

91. Cannon C.P., Blazing M.A., Giugliano R.P., McCagg A., White J.A., Theroux P., Darius H., Lewis B.S., Ophuis T.O., Jukema J.W., de Ferrari G.M., Ruzyllo W., de Lucca P., Im K., Bohula E.A., Reist C., Wiviott S.D., Tershakovec A.M., Musliner T.A., Braunwald E., Califf R.M.; IMPROVE-IT Investigators. Ezetimibe Added to Statin Therapy after Acute Co ronary Syndromes // N. Engl. J. Med. 2015;372:2387–97.

92. Sabatine M.S., Giugliano R.P., Keech A.C., Honarpour N., Wiviott S.D., Murphy S.A., Kuder J.F., Wang H., Liu T., Wasserman S.M., Sever P.S., Pedersen T.R.; FOURIER Steering Committee and Investigators. Evolocumab and Clinical Outcomes in Patients with Cardiovascular Disease // N. Engl. J. Med. 2017;376(18):1713–1722.

93. Raal F.J., Stein E.A., Dufour R., Turner T., Civeira F., Burgess L., Langslet G., Scott R., Olsson A.G., Sullivan D., Hovingh G.K., Cariou B., Gouni-Berthold I., Somaratne R., Bridges I., Scott R., Wasserman S.M., Gaudet D.; RUTHERFORD-2 Investigators. PCSK9 inhibition with evolocumab (AMG 145) in heterozygous familial hypercholesterolaemia (RUTHERFORD-2): a randomised, double-blind, placebo-controlled trial // Lancet 2015;385(9965):331–340.

94. Hovingh G.K., Raal F.J., Dent R., Stefanutti C., Descamps O., Masana L., Lira A., Bridges I., Coll B., Sullivan D. Long-term safety, tolerability, and efficacy of evolocumab in patients with heterozygous familial hypercholesterolemia // J. Clin. Lipidol. 2017;11(6):1448– 1457.

95. Farnier M., Gaudet D., Valcheva V., Minini P., Miller K., Cariou B. Efficacy of alirocumab in heterozygous familial hypercholesterolaemia or high CV risk populations: Pooled analyses of eight phase 3 trials // Atherosclerosis. 2015;241:e25–e26.

96. Raal F.J., Honarpour N., Blom D.J., Hovingh G.K., Xu F., Scott R., Wasserman S.M., Stein E.A.; TESLAInvestigators. Inhibition of PCSK9 with evolocumab in homozygous familial hypercholesterolaemia (TESLA Part B): a randomised, double-blind, placebocontrolled trial // Lancet. 2015;385(9965):341–350.

97. Van der Graaf A., Avis H.J., Kusters D.M., Vissers M.N., Hutten B.A., Defesche J.C., Huijgen R., Fouchier S.W., Wijburg F.A., Kastelein J.J., Wiegman A. Molecular basis of autosomal dominant hypercholesterolemia: assessment in a large cohort of hypercholesterolemic children // Circulation. 2011;123:1167–1173.

98. Wald D.S., Bestwick J.P., Wald N.J. Child-parent screening for familial hypercholesterolaemia: screening strategy based on a meta-analysis // BMJ. 2007; 335:599.

99. Harada-Shiba M., Sugisawa T., Makino H., Abe M., Tsushima M., Yoshimasa Y., Yamashita T., Miyamoto Y., Yamamoto A., Tomoike H., Yokoyama S. Impact of statin treatment on the clinical fate of heterozygous familial hypercholesterolemia // J. Atheroscler. Thromb. 2010;17:667–74.

100. Vuorio A., Doherty K.F., Humphries S.E., Kuoppala J., Kovanen P.T. Statin treatment of children with familial hypercholesterolemia — trying to balance incomplete evidence of long-term safety and clinical accountability: are we approaching a consensus? // Atherosclerosis. 2013;226:315–320.

101. Rodenburg J., Vissers M.N., Wiegman A., van Trotsenburg A.S., van der Graaf A., de Groot E., Wijburg F.A., Kastelein J.J., Hutten B.A. Statin treatment in children with familial hypercholesterolemia: the younger, the better // Circulation. 2007;116:664–668.

102. Knipscheer H.C., Boelen C.C., Kastelein J.J., van Diermen D.E., Groenemeijer B.E., van den Ende A., Buller H.R., Bakker H.D. Short-term efficacy and safety of pravastatin in 72 children with familial hypercholesterolemia // Pediatr. Res. 1996;39:867–871.

103. Stein E.A., Illingworth D.R., Kwiterovich P.O. Jr, Liacouras C.A., Siimes M.A., Jacobson M.S., Brewster T.G., Hopkins P., Davidson M., Graham K., Arensman F., Knopp R.H., DuJovne C., Williams C.L., Isaacsohn J.L., Jacobsen C.A., Laskarzewski P.M., Ames S., Gormley G.J. Efficacy and safety of lovastatin in adolescent males with heterozygous familial hypercholesterolemia: a randomized controlled trial // JAMA. 1999;281: 137–144.

104. Jongh S., Ose L., Szamosi T., Gagne C., Lambert M., Scott R., Perron P., Dobbelaere D., Saborio M., Tuohy M.B., Stepanavage M., Sapre A., Gumbiner B., Mercuri M., van Trotsenburg A.S., Bakker H.D., Kastelein J.J. Efficacy and safety of statin therapy in children with familial hypercholesterolemia: a randomized, double-blind, placebo-controlled trial with simvastatin // Circulation. 2002;106:2231–2237.

105. McCrindle B.W., Ose L., Marais A.D. Efficacy and safety of atorvastatin in children and adolescents with familial hypercholesterolemia or severe hyperlipidemia: a multicenter, randomized, placebo-controlled trial // J. Pediatr. 2003;143:74–80.

106. Wiegman A., Hutten B.A., de Groot E., Rodenburg J., Bakker H.D., Bu¨ller H.R., Sijbrands E.J., Kastelein J.J. Efficacy and safety of statin therapy in children with familial hypercholesterolemia: a randomized controlled trial // JAMA. 2004;292:331–337.

107. Clauss S.B., Holmes K.W., Hopkins P., Stein E., Cho M., Tate A., Johnson-Levonas A.O., Kwiterovich P.O. Efficacy and safety of lovastatin therapy in adolescent girls with heterozygous familial hypercholesterolemia // Pediatrics. 2005;116:682–688.

108. Van der Graaf A., Cuffie-Jackson C., Vissers M.N., Trip M.D., Gagne´ C., Shi G., Veltri E., Avis H.J., Kastelein J.J. Efficacy and safety of coadministration of ezetimibe and simvastatin in adolescents with heterozygous familial hypercholesterolemia // J. Am. Coll. Cardiol. 2008;52:1421–1429.

109. Raal F.J., Pilcher G.J., Panz V.R., van Deventer H.E., Brice B.C., Blom D.J., Marais A.D. Reduction in mortality in subjects with homozygous familial hypercholesterolemia associated with advances in lipidlowering therapy // Circulation. 2011;124:2202–2207.

110. Raal F.J., Pilcher G.J., Illingworth D.R., Pappu A.S., Stein E.A., Laskarzewski P., Mitchel Y.B., Melino M.R. Expanded-dose simvastatin is effective in homozygous familial hypercholesterolemia // Atherosclerosis 1997;135:244–256.

111. Raal F.J., Pappu A.S., Illingworth D.R., Pilcher G.J., Marais A.D., Firth J.C., Kotze M.J., Heinonen T.M., Black D.M. Inhibition of cholesterol synthesis by atorvastatin in homozygous familial hypercholesterolemia // Atherosclerosis. 2000;150:421–428.

112. Marais A.D., Raal F.J., Stein E.A., Rader D.J., Blasetto J., Palmer M., Wilpshaarf W. A dosetitration and comparative study of rosuvastatin and atorvastatin in patients with homozygous familial hypercholesterolemia // Atherosclerosis. 2008;197:400–406.

113. Yamamoto A., Harada-Shiba M., Kawaguchi A., Oi K., Kubo H., Sakai S., Mikami Y., Imai T., Ito T., Kato H., Endo M., Sato I., Suzuki Y., Hori H. The effect of atorvastatin on serum lipids and lipoproteins in patients with homozyous familial hypercholesterolemia undergoing LDL-apheresis therapy // Atherosclerosis. 2000;153:89–98.

114. Marais A.D., Blom D.J., Firth J.C. Statins in homozygous familial hypercholesterolemia // Curr. Atheroscler. Rep. 2002;4:19–25.

115. Gagne C., Gaudet D., Bruckert E. Efficacy and safety of ezetimibe coadministered with atorvastatin or simvastatin in patients with homozygous familial hypercholesterolemia // Circulation. 2002;105:2469– 2475.

116. Thorogood M., Seed M., de Mott K.; Guideline Development Group. Management of fertility in women with familial hypercholesterolaemia: summary of NICE guidance // Br. J. Obstet. Gynaecol. 2009;116:478–479.

117. Thompson G.R., Catapano A., Saheb S., Atassi-Dumont M., Barbir M., Eriksson M., Paulweber B., Sijbrands E., Stalenhoef A.F., Parhofer K.G. Severe hypercholesterolaemia: therapeutic goals and eligibility criteria for LDL apheresis in Europe // Curr. Opin. Lipidol. 2010;21:492–498.

118. Broekhuizen K., Jelsma G.J., van Poppel N.M., Koppes L.L., Brug J., van M.W. Is the process of delivery of an individually tailored lifestyle intervention associated with improvements in LDL cholesterol and multiple lifestyle behaviours in people with Familial Hypercholesterolemia? // BMC Public. Health. 2012;12:348.

119. Broekhuizen K., van Poppel M.N., Koppes L.L., Kindt I., Brug J., van Mechelen W. Can multiple lifestyle behaviours be improved in people with familial hypercholesterolemia? Results of a parallel randomised controlled trial // PLoS One. 2012;7(12):e50032.

120. Michaelides A.P., Fourlas C.A., Pitsavos C., Andrikopoulos G.K., Skoumas I., Kartalis A., Katsaros A., Stougiannos P., Stefanadis C.I. Exercise testing in asymptomatic patients with heterozygous familial hypercholesterolaemia // Coron. Artery. Dis. 2004;15(8):461–465.

121. Conti A.A., Macchi C. Protective effects of regular physical activity on human vascular system // Clin. Ter. 2013;164(4):293–294.

122. Párraga-Martínez I., Escobar-Rabadán F., Rabanales-Sotos J., Lago-Deibe F., Téllez-Lapeira J.M., Villena-Ferrer A., Blasco-Valle M., FerrerasAmez J.M., Morena-Rayo S., Del Campo-Del Campo J.M., Ayuso-Raya M.C., Pérez-Pascual J.J. Efficacy of a Combined Strategy to Improve Low-density Lipoprotein Cholesterol Control Among Patients With Hypercholesterolemia: A Randomized Clinical Trial // Rev. Esp. Cardiol. (Engl Ed). 2018;71(1):33–41.

123. Faggiano P., Pirillo A., Griffo R., Ambrosetti M., Pedretti R., Scorcu G., Werren M., Febo O., Malfatto G., Favretto G., Sarullo F., Antonini-Canterin F., Zobbi G., Temporelli P., Catapano A.L. Prevalence and management of familial hypercholesterolemia in patients with coronary artery disease: The heredity survey // Int. J. Cardiol. 2018;252:193–198.

124. Louter L., Defesche J., Roeters van Lennep J. Cascade screening for familial hypercholesterolemia: Practical consequences // Atheroscler. Suppl. 2017 Nov;30:77–85.

125. Casula M., Catapano A.L., Rossi Bernardi L., Visconti M., Aronica A. Detection of familial hypercholesterolemia in patients from a general practice database // Atheroscler. Suppl. 2017;29:25–30.

126. Benn M., Watts G.F., Tybjaerg-Hansen A., Nordestgaard B.G. Familial hypercholesterolemia in the danish general population: prevalence, coronary artery disease, and cholesterol-lowering medication // J. Clin. Endocrinol. Metab. 2012;97(11):3956–3964.

127. Sharifi M., Rakhit R.D., Humphries S.E., Nair D. Cardiovascular risk stratification in familial hypercholesterolaemia // Heart. 2016;102(13):1003–1008.

128. Jansen A.C., van Aalst-Cohen E.S., Tanck M.W., Trip M.D., Lansberg P.J., Liem A.H., van Lennep H.W., Sijbrands E.J., Kastelein J.J. The contribution of classical risk factorsto cardiovascular disease in familial hypercholesterolaemia: data in 2400 patients // J. Intern. Med. 2004;256:482–490.

129. Torvik K., Narverud I., Ottestad I., Svilaas A., Gran J.M., Retterstøl K., Ellingvеg A., Strøm E., Ose L., Veierød M.B., Holven K.B. Dietary counseling is associated with an improved lipid profile in children with familial hypercholesterolemia // Atherosclerosis. 2016;252:21–27.

130. Descamps O.S., de Meester A., Cheron P., Kastelein J.J., Heller F.R. Silent ischaemia in familial hypercholesterolemia // Atheroscler. Suppl. 2003;4:7–8.

131. Mata N., Alonso R., Banegas J.R., Zambуn D., Brea A., Mata P. Quality of life in a cohort of familial hypercholesterolemia patients from the south of Europe // Eur. J. Public. Health. 2014;24(2):221–225.

132. Antithrombotic Trialists’ Collaboration, Baigent C., Blackwell L., Collins R., Emberson J., Godwin J., Peto R., Buring J., Hennekens C., Kearney P., Meade T., Patrono C., Roncaglioni M.C., Zanchetti A. Aspirin in the primary and secondary prevention of vascular disease: collaborative meta-analysis of individual participant data from randomised trials // Lancet. 2009;373:1849–1860.

133. Eapen D.J., Valiani K., Reddy S., Sperling L. Management of familial hypercholesterolemia during pregnancy: case series and discussion // J. Clin. Lipidol. 2012;6(1):88–91.

134. Vickery A.W., Bell D., Garton-Smith J., Kirke A.B., Pang J., Watts G.F. Optimising the detection and management of familial hypercholesterolaemia: central role of primary care and its integration with specialist services // Heart Lung. Circ. 2014;23(12):1158–1164.

135. Watts G.F., Sullivan D.R., van Bockxmeer F.M., Poplawski N., Hamilton-Craig I., Clifton P.M., O’Brien R.C., Bishop W., George P.M., Semsarian C., Tonkin A.; Familial Hypercholesterolaemia Australasia Network. A new model of care for familial hypercholesterolaemia: what is the role of cardiology? // Heart Lung. Circ. 2012;21(9):543–550.

136. Schonfeld G. Who should treat familial hypercholesterolemia? // Am. J. Cardiol. 1993;72(10):38D–41D.

137. Purchase S., Vickery A., Garton-Smith J., O’Leary P., Sullivan D., Slattery M., Playford D., Watts G. A framework for bridging the gap in the care of familial hypercholesterolaemia in the community: pragmatic and economic perspectives // Int. J. Evid. Based. Healthc. 2014;12(4):244–254.

138. Law M., Rudnicka A.R. Statin safety: a systematic review // Am. J. Cardiol. 2006;97(8A): 52C–60C.

139. Naci H., Brugts J., Ades T. Comparative tolerability and harms of individual statins: a study-level network meta-analysis of 246 955 participants from 135 randomized, controlled trials // Circ. Cardiovasc. Qual. Outcomes 2013;6:390–399.

140. Marcum Z.A., Vande Griend J.P., Linnebur S.A. FDA drug safety communications: a narrative review and clinical considerations for older adults // Am. J. Geriatr. Pharmacother. 2012;10:264–271.

141. Chalasani N., Aljadhey H., Kesterson J., Murray M.D., Hall S.D. Patients with elevated liver enzymes are not at higher risk for statin hepatotoxicity // Gastroenterology. 2004;126:1287–1292.

142. Gandelman K., Glue P., Laskey R., Jones J., LaBadie R., Ose L. An eight-week trial investigating the efficacy and tolerability of atorvastatin for children and adolescents with heterozygous familial hypercholesterolemia // Pediatr. Cardiol. 2011;32(4):433–441.

143. Lennernäs H., Fager G. Pharmacodynamics and pharmacokinetics of the HMG-CoA reductase inhibitors. Similarities and differences // Clin. Pharmacokinet. 1997;32(5):403–425.

144. Coodley G.O., Jorgensen M., Kirschenbaum J., Sparks C., Zeigler L., Albertson B.D. Lowering LDL cholesterol in adults: a prospective, community-based practice initiative // Am. J. Med. 2008;121:604–610.

145. Wiklund O., Pirazzi C., Romeo S. Monitoring of lipids, enzymes, and creatine kinase in patients on lipid-lowering drug therapy // Curr. Cardiol. Rep. 2013;15(9):397.

146. Vongpromek R., Bos S., Ten Kate G.J., Yahya R., Verhoeven A.J., de Feyter P.J., Kronenberg F., Roeters van Lennep J.E., Sijbrands E.J., Mulder M.T. Lipoprotein(a) levels are associated with aortic valve calcification in asymptomatic patients with familial hypercholesterolaemia // J. Intern. Med. 2015;278(2):166–173.

147. Okada H., Tada H., Hayashi K., Kawashima H., Takata T., Sakata K., Nohara A., Mabuchi H., Yamagishi M., Kawashiri M.A. Aortic Root Calcification Score as an Independent Factor for Predicting Major Adverse Cardiac Events in Familial Hypercholesterolemia // J. Atheroscler. Thromb. 2018;25(7):634–642. doi: 10.5551/jat.42705.

148. Kusters D.M., Lahsinoui H.H., van de Post J.A.M., Wiegman A., Wijburg F.A., Kastelein J.J., Hutten B.A. Statin use during pregnancy: a systematic review and meta-analysis // Expert. Rev. Cardiovasc. Ther. 2012;10:363–378.

149. Wiegman A., de Groot E., Hutten B.A., Rodenburg J., Gort J., Bakker H.D., Sijbrands E.J., Kastelein J.J. Arterial intima-media thickness in children heterozygous for familial hypercholesterolaemia // Lancet. 2004;363(9406):369–370.

150. Nemati M.H. Bilateral carotid atherosclerosis: an inevitable consequence of homozygous familial hypercholesterolemia // J. Heart Valve. Dis. 2011;20(3):363–364.

151. Pereira C., Miname M., Makdisse M., Kalil Filho R., Santos R.D. Association of peripheral arterial and cardiovascular diseases in familial hypercholesterolemia // Arq. Bras. Cardiol. 2014. Aug;103(2):118–123. Pérez de Isla L., Alonso R., Mata N., Saltijeral A., Muсiz O., Rubio-Marin P., Diaz-Diaz J.L., Fuentes F., de Andrés R., Zambуn D., Galiana J., Piedecausa M., Aguado R., Mosquera D., Vidal J.I., Ruiz E., Manjуn L., Mauri M., Padrу T., Miramontes J.P., Mata P. Coronary Heart Disease, Peripheral Arterial Disease, and Stroke in Familial Hypercholesterolaemia: Insights From the SAFEHEART Registry (Spanish Familial Hypercholesterolaemia Cohort Study) // Arterioscler. Thromb. Vasc. Biol. 2016;36(9):2004–2010.

152. Aboyans V., Ricco J.B., Bartelink M.E.L., Björck M., Brodmann M., Cohnert T., Collet J.P., Czerny M., de Carlo M., Debus S., Espinola-Klein C., Kahan T., Kownator S., Mazzolai L., Naylor A.R., Roffi M., Röther J., Sprynger M., Tendera M., Tepe G., Venermo M., Vlachopoulos C., Desormais I.; ESC Scientific Document Group. 2017 ESC Guidelines on the Diagnosis and Treatment of Peripheral Arterial Diseases, in collaboration with the European Society for Vascular Surgery (ESVS): Document covering atherosclerotic disease of extracranial carotid and vertebral, mesenteric, renal, upper and lower extremity arteries. Endorsed by: the European Stroke Organization (ESO). The Task Force for the Diagnosis and Treatment of Peripheral Arterial Diseases of the European Society of Cardiology (ESC) and of the European Society for Vascular Surgery (ESVS) // Eur. Heart J. 2018;39(9):763–816.

153. Akioyamen L.E., Genest J., Shan S.D., Reel R.L., Albaum J.M., Chu A., Tu J.V. Estimating the prevalence of heterozygous familial hypercholesterolaemia: a systematic review and meta-analysis // BMJ Open. 2017;7(9):e016461.

154. Thompson G.R. The evidence-base for the efficacy of lipoprotein apheresis in combating cardiovascular diseases // Atheroscler. Suppl. 2013;14(1):67–70.

155. Keller C. LDL-apheresis in homozygous LDL-receptor-defective familial hypercholesterolemia: the Munich experience // Atheroscler. Suppl. 2009;10(5):21–26.

156. Gordon B.R., Kelsey S.F., Dau P.C., Gotto A.M. Jr., Graham K., Illingworth D.R., Isaacsohn J., Jones P.H., Leitman S.F., Saal S.D., Stein E.A., Stern T.N., Troendle A., Zwiener R.J. Long-term effects of lowdensity lipoprotein apheresis using an automated dextran sulfate cellulose adsorption system. Liposorber Study Group // Am. J. Cardiol. 1998. Vol. 81, N 4. P. 407–411.

157. Kitano Y., Thompson G.R. The familial hypercholesterolemia regression study: a randomized comparison of therapeutic reduction of both low-density lipoprotein and lipoprotein(a) versus low-density lipoprotein alone // Ther. Apher. 1997. Vol. 1, N 2. P. 187–190.

158. Tatami R., Inoue N., Itoh H., Kishino B., Koga N., Nakashima Y., Nishide T., Okamura K., Saito Y., Teramoto T. Regression of coronary atherosclerosis by combined LDL-apheresis and lipid-lowering drug therapy in patients with familial hypercholesterolemia: a multicenter study. The LARS Investigators // Atherosclerosis. 1992. Vol. 95, N 1. P. 1–13.

159. Tishko V.V. Long-term results of the effect of efferent therapy on the incidence of angiographic restenosis of the coronary arteries in patients with stable exertional angina after coronary angioplasty and stenting // Bull. Rus. Milit. Med. Acad. 2015. Vol. 49, N 1. C. 7–12. Russian.

160. Ezhov M.V., Il’ina L.N., Safarova M.S., Afanasieva O.I., Adamova I.Y., Atanesyan R.V., Konovalov G.A., Akchurin R.S., Pokrovsky S.N. Cascade plasma filtration during the first year after CABG in patients with hyperlipidemia refractory to statins // Atheroscler. Suppl. 2013. Vol. 14, N 1. P. 101–105.

161. Matsuzaki M., Hiramori K., Imaizumi T., Kitabatake A., Hishida H., Nomura M., Fujii T., Sakuma I., Fukami K., Honda T., Ogawa H., Yamagishi M. Intravascular ultrasound evaluation of coronary plaque regression by low density lipoprotein-apheresis in familial hypercholesterolemia: the Low Density Lipoprotein-Apheresis Coronary Morphology and Reserve Trial (LACMART) // J. Am. Coll. Cardiol. 2002. Vol. 40, N 2. P. 220–227.

162. Nishimura S., Sekiguchi M., Kano T., Ishiwata S., Nagasaki F., Nishide T., Okimoto T., Kutsumi Y., Kuwabara Y., Takatsu F., Nishikawa H., Daida H., Yamaguchi H. Effects of intensive lipid lowering by low-density lipoprotein apheresis on regression of coronary atherosclerosis in patients with familial hypercholesterolemia: Japan Low-density Lipoprotein Apheresis Coronary Atherosclerosis Prospective Study (L-CAPS) // Atherosclerosis. 1999. Vol. 144, N 2. P. 409–417.

163. Mabuchi H., Koizumi J., Shimizu M., Kajinami K., Miyamoto S., Ueda K., Takegoshi T. Long-term efficacy of low-density lipoprotein apheresis on coronary heart disease in familial hypercholesterolemia. Hokuriku-FH-LDL-Apheresis Study Group // Am. J. Cardiol. 1998. Vol. 82, N 12. P. 1489–1495.

164. Kroon A.A., Aengevaeren W.R., van der Werf T., Uijen G.J., Reiber J.H., Bruschke A.V., Stalenhoef A.F. LDL-Apheresis Atherosclerosis Regression Study (LAARS). Effect of aggressive versus conventional lipid lowering treatment on coronary atherosclerosis // Circulation. 1996. Vol. 93, N 10. P. 1826–1835.

165. Schatz U., Tselmin S., Muller G., Julius U., Hohenstein B., Fischer S., Bornstein S.R. Most significant reduction of cardiovascular events in patients undergoing lipoproteinapheresis due to raised Lp(a) levels – A multicenter observational study // Atheroscler. Suppl. 2017. Vol. 30. P. 246–252.

166. Klingel R., Heibges A., Fassbender C., ProLiFeStudy G. Prevention of cardiovascular complications in patients with Lp(a)-hyperlipoproteinemia and progressive cardiovascular disease by long-term lipoprotein apheresis according to German national guidelines // Clin. Res. Cardiol. Suppl. 2017. Vol. 12, Suppl. 1. P. 38–43.

167. Pokrovsky S.N., Afanasieva O.I., Safarova M.S., Balakhonova T.V., Matchin Yu.G., Adamova I.Yu., Konovalov G.A., Ezhov M.V. Specific Lp(a) apheresis: A tool to prove lipoprotein(a) atherogenicity // Atheroscler. Suppl. 2017. Vol. 30. P. 166–173.

168. Khan T.Z., Hsu L.Y., Arai A.E., Rhodes S., Pottle A., Wage R., Banya W., Gatehouse P.D., Giri S., Collins P., Pennell D.J., Barbir M. Apheresis as novel treatment for refractory angina with raised lipoprotein(a): a randomized controlled cross-over trial // Eur. Heart. J. 2017. Vol. 38, N 20. P. 1561– 1569.

169. Hohenstein B., Julius U., Lansberg P., Jaeger B., Mellwig K.P., Weiss N., Graehlert X., Roeder I., Ramlow W. Rationale and design of MultiSELECt: A European Multicenter Study on the Effect of Lipoprotein(a) Elimination by lipoprotein apheresis on Cardiovascular outcomes // Atheroscler. Suppl. 2017. Vol. 30. P. 180–186.

170. Heigl F., Hettich R., Lotz N., Reeg H., Pflederer T., Osterkorn D., Osterkorn K., Klingel R. Efficacy, safety, and tolerability of long-term lipoprotein apheresis in patients with LDL- or Lp(a) hyperlipoproteinemia: Findings gathered from more than 36,000 treatments at one center in Germany // Atheroscler. Suppl. 2015. Vol. 18. P. 154–162.

171. Safarova M.S., Ezhov M.V., Afanasieva O.I., Matchin Yu.G., Atanesyan R.V., Adamova I.Yu., Utkina E.A., Konovalov G.A., Pokrovsky S.N. Effect of specific Lp(a) apheresis on coronary atherosclerosis regression assessed by quantitative coronary angiography // Atheroscler. Suppl. 2013. Vol. 14. P. 93–99.

172. Anedda S., Mura S., Marcello C., Pintus P. HELP LDL-apheresis in two cases of familial hypercholesterolemic pregnant women // Transfus. Apher. Sci. 2011. Vol. 44, N 1. P. 21–24.

173. Ertorer M.E., Guvenc B., Haydardedeoglu B., Tekinturhan F. A case report of the cascade filtration system: a safe and effective method for low-density lipoprotein apheresis during pregnancy // Ther. Apher Dial. 2008. Vol. 12, N 5. P. 396–400.

174. Cashin-Hemphill L., Noone M., Abbott J.F., Waksmonski C.A., Lees R.S. Low-density lipoprotein apheresis therapy during pregnancy // Am. J. Cardiol. 2000. Vol. 86, N 10. P. 1160, A10.

175. Civeira F., Ros E., Jarauta E., Plana N., Zambon D., Puzo J., Martinez de Esteban J.P., Ferrando J., Zabala S., Almagro F., Gimeno J.A., Masana L., Pocovi M. Comparison of genetic versus clinical diagnosis in familial hypercholesterolemia // Am. J. Cardiol. 2008; 102:1187–1193.

176. Palacios L., Grandoso L., Cuevas N., Olano-Martin E., Martinez A., Tejedor D., Stef M. Molecular characterization of familial hypercholesterolemia in Spain // Atherosclerosis 2012;221:137–142.

177. Raal F.J., Hovingh G.K., Blom D., Santos R.D., Harada-Shiba M., Bruckert E., Couture P., Soran H., Watts G.F., Kurtz C., Honarpour N., Tang L., Kasichayanula S., Wasserman S.M., Stein E.A. Longterm treatment with evolocumab added to conventional drug therapy, with or without apheresis, in patients with homozygous familial hypercholesterolaemia: an interim subset analysis of the open-label TAUSSIG study // Lancet Diabetes Endocrinol. 2017;5(4):280–290.

178. Sokolov A.A., Aleksandrova O.Yu., Kashtalap V.V., Barbarash O.L., Ezhov M.V. Guidelines for the organization of medical care for patients with hereditary atherogenic lipid metabolism disorders in the subjects of the Russian Federation // Atherosclerosis and dyslipidemia. 2016; 4 (25): 14–20. Russin).

179. Athyros V.G., Tziomalos K., Kakafika A.I., Koumaras H., Karagiannis A., Mikhailidis D.P. Effectiveness of ezetimibe alone or in combination with twice a week atorvastatin (10 mg) for statin intolerant highrisk patients // Am. J. Cardiol. 2008;101:483–485.

180. Stein E.A., Ballantyne C.M., Windler E., Sirnes P.A., Sussekov A., Yigit Z., Seper C., Gimpelewicz C.R. Efficacy and tolerability of Fluvastatin XL 80 mg alone, ezetimibe alone and the combination of Fluvastatin XL 80 mg with ezetimibe in patients with a history of muscle-related side effects with other statins: a randomized, doubleblind, double-dummy trial // Am. J. Cardiol. 2008;101:490–496.

181. Stroes E., Colquhoun D., Sullivan D., Civeira F., Rosenson R.S., Watts G.F., Bruckert E., Cho L., Dent R., Knusel B., Xue A., Scott R., Wasserman S.M., Rocco M.; GAUSS-2 Investigators. Anti-PCSK9 antibody effectively lowers cholesterol in patients with statin intolerance: the GAUSS-2 randomized, placebo-controlled phase 3 clinical trial of evolocumab // J. Am. Coll. Cardiol. 2014;63(23):2541–2548.

182. Nissen S.E., Stroes E., Dent-Acosta R.E., Rosenson R.S., Lehman S.J., Sattar N., Preiss D., Bruckert E., Ceška R., Lepor N., Ballantyne C.M., Gouni-Berthold I., Elliott M., Brennan D.M., Wasserman S.M., Somaratne R., Scott R., Stein E.A.; GAUSS-3 Investigators.Efficacy and Tolerability of Evolocumab vs Ezetimibe in Patients With Muscle-Related Statin Intolerance: The GAUSS-3 Randomized Clinical Trial // JAMA. 2016;315(15):1580–1590.

183. Moriarty P.M., Thompson P.D., Cannon C.P., Guyton J.R., Bergeron J., Zieve F.J., Bruckert E., Jacobson T.A., Kopecky S.L., Baccara-Dinet M.T., Du Y., Pordy R., Gipe D.A.; ODYSSEY ALTERNATIVE Investigators.. Efficacy and safety of alirocumab vs ezetimibe in statin-intolerant patients, with a statinrechallenge arm: The ODYSSEY ALTERNATIVE randomized trial // J. Clin. Lipidol. 2015;9(6):758–769.

184. Banach M., Rizzo M., Toth P.P., Farnier M., Davidson M.H., Al-Rasadi K., Aronow W.S., Athyros V., Djuric D.M., Ezhov M.V., Greenfield R.S., Hovingh G.K., Kostner K., Serban C., Lighezan D., Fras Z., Moriarty P.M., Muntner P., Goudev A., Ceska R., Nicholls S.J., Broncel M., Nikolic D., Pella D., Puri R., Rysz J., Wong N.D., Bajnok L., Jones S.R., Ray K.K., Mikhailidis D.P. Statin intolerance – an attempt at a unified definition. Position paper from an International Lipid Expert Panel // Arch. Med. Sci. 2015;11(1):1–23.